TechNavio's analysts forecast the Global Diabetic Retinopathy Market to grow at a CAGR of 35.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the Increase in Diabetic Population Worldwide. The Global Diabetic Retinopathy Market has also been witnessing the Increased Focus on Combination Therapies. However, the Availability of Effective Surgical Treatments could pose a challenge to the growth of this market.
TechNavio's report, the Global Diabetic Retinopathy Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC region; it also covers the Global Diabetic Retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Eli Lilly and Co., Novartis International AG, Pfizer Inc., and Roche Holding Ltd.
Other vendors mentioned in the report are Alcon Inc., Allergan Inc., Ampio Pharmaceuticals Inc., Anadys Pharmaceuticals Inc., Antisense Therapeutics Ltd., Boehringer Ingelheim GmbH, DeveloGen AG, Excaliard Pharmaceuticals Inc., Eyetech Inc., Ferrosan Holding A/S, FoldRx Pharmaceuticals Inc., iCo Therapeutics Inc., Intercell AG, Isis Pharmaceuticals Inc., King Pharmaceuticals Inc., Lpath Inc., Lupin Ltd., mtm laboratories AG, Novagali Pharma SA, Novast Laboratories Ltd., OPKO Health Inc., PAREXEL International Corp., pSivida Corp., Quark Pharmaceuticals Inc., Sirnaomics Inc., ThromboGenics NV, Torrent Pharmaceuticals Ltd., and Vitreoretinal Technologies Inc.
Key questions answered in this report:
What will the market size be in 2016 and at what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.
01. Executive Summary
02. List of Abbreviations
04. Scope of the Report
04.1 Product Offerings
05. Market Landscape
Market Size and Forecast
05.1Five Force Analysis
06. Geographical Segmentation
07. Vendor Landscape
08. Buying Criteria
09. Diabetic Retinopathy Drugs in the Pipeline
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Roche Holding Ltd.
15.2 Novartis International AG.
15.3 Pfizer Inc.
15.4 Eli Lilly and Co.
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Diabetic Retinopathy Drugs Market 2012-2016(US$ million)
Exhibit 2: Global Diabetic Retinopathy Drugs Market by Geographical Segmentation 2012
Exhibit 3: Business Segmentation of Roche Holding Ltd
Exhibit 4: Business Segmentation of Novartis International AG
Exhibit 5: Business Segmentation of Pfizer Inc.
Exhibit 6: Business Segmentation of Eli Lilly and Co.